North America dominated the global respiratory virus infection drugs market in 2019. The trend is anticipated to continue during the forecast period. Strategies adopted by key players, such as product approvals & launch and mergers & acquisitions, well-established healthcare infrastructure, and early adoption of advanced therapeutics boost the growth of the respiratory virus infection drugs treatment market in the region.
This report aims to provide a comprehensive presentation of the global market for Respiratory Virus Infection Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Virus Infection Drugs. This report contains market size and forecasts of Respiratory Virus Infection Drugs in global, including the following market information:
Global Respiratory Virus Infection Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Respiratory Virus Infection Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Antibiotics Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Respiratory Virus Infection Drugs include GlaxoSmithKline plc, Merck and Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, CHIESI Farmaceutici S.p.A. and Orion Corporation, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Respiratory Virus Infection Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Respiratory Virus Infection Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Respiratory Virus Infection Drugs Market Segment Percentages, by Type, 2022 (%)
Antibiotics
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Cough Suppressants
Nasal Decongestants
Others
Global Respiratory Virus Infection Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Respiratory Virus Infection Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Clinics
Others
Global Respiratory Virus Infection Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Respiratory Virus Infection Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Respiratory Virus Infection Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Respiratory Virus Infection Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline plc
Merck and Co., Inc.
AstraZeneca
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sanofi
CHIESI Farmaceutici S.p.A.
Orion Corporation
Cipla, Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Respiratory Virus Infection Drugs, market overview.
Chapter 2: Global Respiratory Virus Infection Drugs market size in revenue.
Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Respiratory Virus Infection Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Respiratory Virus Infection Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Respiratory Virus Infection Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Respiratory Virus Infection Drugs Overall Market Size
2.1 Global Respiratory Virus Infection Drugs Market Size: 2022 VS 2030
2.2 Global Respiratory Virus Infection Drugs Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Respiratory Virus Infection Drugs Players in Global Market
3.2 Top Global Respiratory Virus Infection Drugs Companies Ranked by Revenue
3.3 Global Respiratory Virus Infection Drugs Revenue by Companies
3.4 Top 3 and Top 5 Respiratory Virus Infection Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Respiratory Virus Infection Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Respiratory Virus Infection Drugs Players in Global Market
3.6.1 List of Global Tier 1 Respiratory Virus Infection Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Respiratory Virus Infection Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Respiratory Virus Infection Drugs Market Size Markets, 2022 & 2030
4.1.2 Antibiotics
4.1.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
4.1.4 Cough Suppressants
4.1.5 Nasal Decongestants
4.1.6 Others
4.2 By Type - Global Respiratory Virus Infection Drugs Revenue & Forecasts
4.2.1 By Type - Global Respiratory Virus Infection Drugs Revenue, 2018-2023
4.2.2 By Type - Global Respiratory Virus Infection Drugs Revenue, 2024-2030
4.2.3 By Type - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Respiratory Virus Infection Drugs Market Size, 2022 & 2030
5.1.2 Hospital Pharmacies
5.1.3 Drug Stores
5.1.4 Retail Pharmacies
5.1.5 Clinics
5.1.6 Others
5.2 By Application - Global Respiratory Virus Infection Drugs Revenue & Forecasts
5.2.1 By Application - Global Respiratory Virus Infection Drugs Revenue, 2018-2023
5.2.2 By Application - Global Respiratory Virus Infection Drugs Revenue, 2024-2030
5.2.3 By Application - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Respiratory Virus Infection Drugs Market Size, 2022 & 2030
6.2 By Region - Global Respiratory Virus Infection Drugs Revenue & Forecasts
6.2.1 By Region - Global Respiratory Virus Infection Drugs Revenue, 2018-2023
6.2.2 By Region - Global Respiratory Virus Infection Drugs Revenue, 2024-2030
6.2.3 By Region - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Respiratory Virus Infection Drugs Revenue, 2018-2030
6.3.2 US Respiratory Virus Infection Drugs Market Size, 2018-2030
6.3.3 Canada Respiratory Virus Infection Drugs Market Size, 2018-2030
6.3.4 Mexico Respiratory Virus Infection Drugs Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Respiratory Virus Infection Drugs Revenue, 2018-2030
6.4.2 Germany Respiratory Virus Infection Drugs Market Size, 2018-2030
6.4.3 France Respiratory Virus Infection Drugs Market Size, 2018-2030
6.4.4 U.K. Respiratory Virus Infection Drugs Market Size, 2018-2030
6.4.5 Italy Respiratory Virus Infection Drugs Market Size, 2018-2030
6.4.6 Russia Respiratory Virus Infection Drugs Market Size, 2018-2030
6.4.7 Nordic Countries Respiratory Virus Infection Drugs Market Size, 2018-2030
6.4.8 Benelux Respiratory Virus Infection Drugs Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Respiratory Virus Infection Drugs Revenue, 2018-2030
6.5.2 China Respiratory Virus Infection Drugs Market Size, 2018-2030
6.5.3 Japan Respiratory Virus Infection Drugs Market Size, 2018-2030
6.5.4 South Korea Respiratory Virus Infection Drugs Market Size, 2018-2030
6.5.5 Southeast Asia Respiratory Virus Infection Drugs Market Size, 2018-2030
6.5.6 India Respiratory Virus Infection Drugs Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Respiratory Virus Infection Drugs Revenue, 2018-2030
6.6.2 Brazil Respiratory Virus Infection Drugs Market Size, 2018-2030
6.6.3 Argentina Respiratory Virus Infection Drugs Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Respiratory Virus Infection Drugs Revenue, 2018-2030
6.7.2 Turkey Respiratory Virus Infection Drugs Market Size, 2018-2030
6.7.3 Israel Respiratory Virus Infection Drugs Market Size, 2018-2030
6.7.4 Saudi Arabia Respiratory Virus Infection Drugs Market Size, 2018-2030
6.7.5 UAE Respiratory Virus Infection Drugs Market Size, 2018-2030
7 Respiratory Virus Infection Drugs Companies Profiles
7.1 GlaxoSmithKline plc
7.1.1 GlaxoSmithKline plc Company Summary
7.1.2 GlaxoSmithKline plc Business Overview
7.1.3 GlaxoSmithKline plc Respiratory Virus Infection Drugs Major Product Offerings
7.1.4 GlaxoSmithKline plc Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.1.5 GlaxoSmithKline plc Key News & Latest Developments
7.2 Merck and Co., Inc.
7.2.1 Merck and Co., Inc. Company Summary
7.2.2 Merck and Co., Inc. Business Overview
7.2.3 Merck and Co., Inc. Respiratory Virus Infection Drugs Major Product Offerings
7.2.4 Merck and Co., Inc. Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.2.5 Merck and Co., Inc. Key News & Latest Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Company Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Respiratory Virus Infection Drugs Major Product Offerings
7.3.4 AstraZeneca Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.3.5 AstraZeneca Key News & Latest Developments
7.4 Boehringer Ingelheim International GmbH
7.4.1 Boehringer Ingelheim International GmbH Company Summary
7.4.2 Boehringer Ingelheim International GmbH Business Overview
7.4.3 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Major Product Offerings
7.4.4 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.4.5 Boehringer Ingelheim International GmbH Key News & Latest Developments
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 F. Hoffmann-La Roche Ltd. Company Summary
7.5.2 F. Hoffmann-La Roche Ltd. Business Overview
7.5.3 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Major Product Offerings
7.5.4 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.5.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.6.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.6.3 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Major Product Offerings
7.6.4 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.6.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
7.7 Sanofi
7.7.1 Sanofi Company Summary
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Respiratory Virus Infection Drugs Major Product Offerings
7.7.4 Sanofi Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.7.5 Sanofi Key News & Latest Developments
7.8 CHIESI Farmaceutici S.p.A.
7.8.1 CHIESI Farmaceutici S.p.A. Company Summary
7.8.2 CHIESI Farmaceutici S.p.A. Business Overview
7.8.3 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Major Product Offerings
7.8.4 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.8.5 CHIESI Farmaceutici S.p.A. Key News & Latest Developments
7.9 Orion Corporation
7.9.1 Orion Corporation Company Summary
7.9.2 Orion Corporation Business Overview
7.9.3 Orion Corporation Respiratory Virus Infection Drugs Major Product Offerings
7.9.4 Orion Corporation Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.9.5 Orion Corporation Key News & Latest Developments
7.10 Cipla, Inc.
7.10.1 Cipla, Inc. Company Summary
7.10.2 Cipla, Inc. Business Overview
7.10.3 Cipla, Inc. Respiratory Virus Infection Drugs Major Product Offerings
7.10.4 Cipla, Inc. Respiratory Virus Infection Drugs Revenue in Global Market (2018-2023)
7.10.5 Cipla, Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Respiratory Virus Infection Drugs Market Opportunities & Trends in Global Market
Table 2. Respiratory Virus Infection Drugs Market Drivers in Global Market
Table 3. Respiratory Virus Infection Drugs Market Restraints in Global Market
Table 4. Key Players of Respiratory Virus Infection Drugs in Global Market
Table 5. Top Respiratory Virus Infection Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Respiratory Virus Infection Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Respiratory Virus Infection Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Respiratory Virus Infection Drugs Product Type
Table 9. List of Global Tier 1 Respiratory Virus Infection Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Respiratory Virus Infection Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Respiratory Virus Infection Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Respiratory Virus Infection Drugs Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Respiratory Virus Infection Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Respiratory Virus Infection Drugs Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Respiratory Virus Infection Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Respiratory Virus Infection Drugs Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2024-2030
Table 30. GlaxoSmithKline plc Company Summary
Table 31. GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Offerings
Table 32. GlaxoSmithKline plc Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. GlaxoSmithKline plc Key News & Latest Developments
Table 34. Merck and Co., Inc. Company Summary
Table 35. Merck and Co., Inc. Respiratory Virus Infection Drugs Product Offerings
Table 36. Merck and Co., Inc. Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Merck and Co., Inc. Key News & Latest Developments
Table 38. AstraZeneca Company Summary
Table 39. AstraZeneca Respiratory Virus Infection Drugs Product Offerings
Table 40. AstraZeneca Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. AstraZeneca Key News & Latest Developments
Table 42. Boehringer Ingelheim International GmbH Company Summary
Table 43. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Offerings
Table 44. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Boehringer Ingelheim International GmbH Key News & Latest Developments
Table 46. F. Hoffmann-La Roche Ltd. Company Summary
Table 47. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Offerings
Table 48. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 50. Teva Pharmaceutical Industries Ltd. Company Summary
Table 51. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Offerings
Table 52. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
Table 54. Sanofi Company Summary
Table 55. Sanofi Respiratory Virus Infection Drugs Product Offerings
Table 56. Sanofi Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Sanofi Key News & Latest Developments
Table 58. CHIESI Farmaceutici S.p.A. Company Summary
Table 59. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Offerings
Table 60. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. CHIESI Farmaceutici S.p.A. Key News & Latest Developments
Table 62. Orion Corporation Company Summary
Table 63. Orion Corporation Respiratory Virus Infection Drugs Product Offerings
Table 64. Orion Corporation Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Orion Corporation Key News & Latest Developments
Table 66. Cipla, Inc. Company Summary
Table 67. Cipla, Inc. Respiratory Virus Infection Drugs Product Offerings
Table 68. Cipla, Inc. Respiratory Virus Infection Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Cipla, Inc. Key News & Latest Developments
List of Figures
Figure 1. Respiratory Virus Infection Drugs Segment by Type in 2022
Figure 2. Respiratory Virus Infection Drugs Segment by Application in 2022
Figure 3. Global Respiratory Virus Infection Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Respiratory Virus Infection Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Respiratory Virus Infection Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Respiratory Virus Infection Drugs Revenue in 2022
Figure 8. By Type - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 9. By Application - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 10. By Type - Global Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 12. By Application - Global Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 14. By Region - Global Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 15. By Country - North America Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 16. US Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 20. Germany Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 21. France Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 28. China Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. India Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 34. Brazil Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Respiratory Virus Infection Drugs Revenue Market Share, 2018-2030
Figure 37. Turkey Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Respiratory Virus Infection Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. GlaxoSmithKline plc Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck and Co., Inc. Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AstraZeneca Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Sanofi Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Orion Corporation Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Cipla, Inc. Respiratory Virus Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
